The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower ...
Novo Nordisk said on Thursday it has not yet posted details about a new trial of its experimental next-generation obesity drug CagriSema, which it announced it would start after late-stage trial data ...
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Novo Nordisk (NVO), the maker of the popular GLP-1 medications Wegovy and Ozempic, said potential tariffs on Europe imposed ...
European shares saw a rise driven by healthcare giants GSK and Novo Nordisk following robust quarterly results. Novo Nordisk's strong profits from its drug Wegovy and GSK's share buyback plan boosted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback